Some of the topics covered include:
- What is AI and how is it being applied to drug discovery? Why now?
- What are computers good at versus humans and where is the intersection?
- How does AI-driven drug discovery and development impact cost and timelines?
- Is AI a data play? An analytics play? Or something different?
- How do AI applications define specific point problems in drug discovery?
- Are all companies using AI for drug discovery in a similar manner?
- Does AI in drug discovery lend itself to repurposing, NCE, or something different?
- How do you deal with intellectual property?
- Is business model innovation required or can existing models be leveraged? Either for AI startups or large pharma? Can you speak to deals in this space?
- What’s different about integrating AI in drug discovery as opposed to biology-based platform technologies?
- Why and how is large pharma engaging with AI startups? What are they doing internally?
webinar SPEAKERS:

twoXAR

John M. Baldoni, Senior Vice President, Platform Technology and Science (PTS), PhD (Panelist)
GSK Pharma R&D

Craig Mak, Editor, PhD (Moderator)
Cell Systems - Cell Press

Mark Ashwell, Senior Vice President, Chemistry, PhD (Panelist)
Nimbus
SPONSORED BY:

